These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30452612)

  • 21. Prescription of Statins to Women Poses New Clinical Challenges.
    Pung M; Robishaw J; Pfeffer MA; Hennekens CH
    Am J Med; 2018 Oct; 131(10):1139-1140. PubMed ID: 29679537
    [No Abstract]   [Full Text] [Related]  

  • 22. The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk.
    Mangalmurti SS; Davidson MH
    Curr Atheroscler Rep; 2011 Oct; 13(5):373-80. PubMed ID: 21773803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths.
    Virani SS
    Tex Heart Inst J; 2013; 40(3):288-9. PubMed ID: 23914021
    [No Abstract]   [Full Text] [Related]  

  • 24. Aspirin usage pre-race to prevent cardiac arrest in marathon runners during races.
    Siegel AJ
    Am J Med; 2013 Dec; 126(12):e47. PubMed ID: 24262748
    [No Abstract]   [Full Text] [Related]  

  • 25. Preventing Cardiovascular Disease.
    DiNicolantonio JJ; O'Keefe JH
    Prog Cardiovasc Dis; 2016; 58(5):463. PubMed ID: 26875628
    [No Abstract]   [Full Text] [Related]  

  • 26. The PROSPER trial.
    Mascitelli L; Pezzetta F;
    Lancet; 2003 Feb; 361(9355):427; author reply 428. PubMed ID: 12573394
    [No Abstract]   [Full Text] [Related]  

  • 27. Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus.
    Srikanth S; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):47-70. PubMed ID: 21257100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The heart of the matter: reducing CVD risk.
    Hayman LL; Kamau MW; Stuart-Shor EM
    Nurse Pract; 2009 May; 34(5):30-5. PubMed ID: 19390396
    [No Abstract]   [Full Text] [Related]  

  • 29. [Beyond risk factors: priorities and new challenges of cardiovascular prevention].
    Urbinati S; Giampaoli S
    G Ital Cardiol (Rome); 2010 May; 11(5 Suppl 3):7S-14S. PubMed ID: 20879472
    [No Abstract]   [Full Text] [Related]  

  • 30. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
    Boytsov S; Logunova N; Khomitskaya Y;
    Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Part I. Fibrates in primary and secondary prevention].
    Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():3-10. PubMed ID: 27473465
    [No Abstract]   [Full Text] [Related]  

  • 32. What is the role of statins in the elderly population?
    Stavropoulos K; Imprialos K; Doumas M; Athyros VG
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):329-331. PubMed ID: 29431524
    [No Abstract]   [Full Text] [Related]  

  • 33. The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
    Bem D; Lordkipanidzé M; Hodgkinson J; Stevens S; Bayliss S; Moore D; Fitzmaurice D; Dretzke J
    Clin Pharmacol Ther; 2016 Nov; 100(5):500-512. PubMed ID: 27449968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term management of patients at high cardiovascular risk in general practice].
    Filippi A;
    Monaldi Arch Chest Dis; 2009 Dec; 72(4):179-89. PubMed ID: 20183956
    [No Abstract]   [Full Text] [Related]  

  • 35. EJPC @ a glance: focus issue on cardiovascular risk prediction in primary and secondary prevention.
    Tsaban G; Aboyans V
    Eur J Prev Cardiol; 2024 Oct; 31(14):1668-1670. PubMed ID: 39270738
    [No Abstract]   [Full Text] [Related]  

  • 36. Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry.
    Lowenstern AM; Li S; Navar AM; Roger VL; Robinson JG; Goldberg AC; Virani SS; Lee LV; Wilson PWF; Louie MJ; Peterson ED; Wang TY
    J Am Heart Assoc; 2018 Sep; 7(18):e009251. PubMed ID: 30371214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging clinical challenges in the use of statins.
    Hennekens CH; Breuer NR; Gelb IJ; Bjorkman DJ; Borer JS; Pfeffer MA
    Am J Med; 2013 Aug; 126(8):663-4. PubMed ID: 23786669
    [No Abstract]   [Full Text] [Related]  

  • 39. Non-alcoholic fatty liver disease and cardiovascular risk: an update.
    Mullish BH; Forlano R; Manousou P; Mikhailidis DP
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1175-1177. PubMed ID: 30791787
    [No Abstract]   [Full Text] [Related]  

  • 40. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.